SCISPARC LTD. (SPRC): 5 Analyse des forces [Jan-2025 MISE À JOUR]

Dans le monde de pointe des cannabinoïdes thérapeutiques, Scisparc Ltd. (SPRC) navigue dans un paysage complexe de défis et d'opportunités stratégiques. En tant qu'entreprise pionnière dans la recherche neurologique et les solutions de cannabis médical, le SPRC doit analyser soigneusement son environnement concurrentiel grâce au cadre des cinq forces de Michael Porter. Cette plongée profonde révèle la dynamique complexe des relations avec les fournisseurs, les exigences des clients, la concurrence sur le marché, les substituts potentiels et les obstacles à l'entrée qui façonneront finalement le positionnement stratégique et le succès futur de l'entreprise dans l'écosystème innovante pharmaceutique en évolution rapide.

SCISPARC LTD. (SPRC) - Porter's Five Forces: Bargaining Power of Fournissers

Nombre limité de fournisseurs de recherche et de production spécialisés sur les cannabinoïdes

Depuis 2024, le marché de l'offre de recherche sur les cannabinoïdes démontre une concentration importante:

Dépendance potentielle à l'égard des fabricants d'ingrédients pharmaceutiques spécifiques

Le paysage des fournisseurs de SCISPARC révèle des dépendances critiques:

• 3 fournisseurs primaires contrôlent 68,5% des matières premières cannabinoïdes spécialisées
• Durée du contrat moyen: 24 à 36 mois
• Accords d'approvisionnement exclusifs avec 2 fabricants clés

Coûts de commutation élevés pour les matériaux de recherche sur les cannabinoïdes spécialisés

Marché des fournisseurs concentrés avec peu de sources alternatives

L'analyse du marché indique:

• Fournisseurs de matériaux de recherche sur les cannabinoïdes mondiaux: 15
• Fournisseurs rencontrant les normes de la FDA / EMA: 7
• Fournisseurs avec certification GMP: 5

SCISPARC LTD. (SPRC) - Porter's Five Forces: Bargaining Power of Clients

Institutions de recherche pharmaceutique et sociétés de cannabis médical

SCISPARC Ltd. dessert une clientèle spécialisée avec les caractéristiques du marché suivantes:

Analyse de la sensibilité aux prix

Métriques de sensibilité au prix du client pour les solutions neurologiques:

• Sensibilité à la recherche et au développement des coûts: 78%
• Élasticité des prix sur les marchés thérapeutiques: 0,65
• Plage de négociation contractuelle moyenne: 12-18%

Exigences thérapeutiques spécialisées

SCISPARC LTD. (SPRC) - Porter's Five Forces: Rivalry compétitif

Paysage compétitif Overview

En 2024, SCISPARC Ltd. opère dans un marché de recherche thérapeutique à base de cannabinoïdes hautement compétitif avec la dynamique concurrentielle suivante:

Investissement de la recherche et du développement

Métriques d'investissement en R&D de SCISPARC:

• 2023 dépenses de R&D: 4,2 millions de dollars
• Budget de R&D projeté en 2024: 5,7 millions de dollars
• Personnel de recherche: 22 scientifiques spécialisés

Analyse de la pression concurrentielle

Marché des indicateurs compétitifs

Métriques quantitatives du paysage concurrentiel:

• Taille totale du marché adressable: 1,3 milliard de dollars
• Taux de croissance du marché: 15,6% par an
• Nombre de brevets actifs dans la recherche neurologique sur les cannabinoïdes: 42

SCISPARC LTD. (SPRC) - Five Forces de Porter: Menace de substituts

Thérapies alternatives de gestion de la douleur et de traitement neurologique

En 2024, le marché mondial de la gestion de la douleur alternative est évalué à 81,2 milliards de dollars, présentant un potentiel de substitution important pour les traitements neurologiques de SCISPARC.

Interventions pharmaceutiques émergentes non cannabinoïdes

Les alternatives pharmaceutiques émergentes démontrent un potentiel de marché substantiel.

• Marché du traitement des maladies neurodégénératives: 52,6 milliards de dollars
• Interventions neurologiques de la médecine de précision: 37,9 milliards de dollars
• Traitements neurologiques de la thérapie génique: 14,3 milliards de dollars

Approches pharmaceutiques traditionnelles des conditions neurologiques

Les marchés pharmaceutiques traditionnels présentent des risques de substitution importants.

Les alternatives génériques de médicament réduisent potentiellement l'attractivité du marché

La dynamique générique du marché des médicaments a un impact sur le potentiel de substitution.

• Marché mondial des médicaments génériques: 407,3 milliards de dollars
• Segment de médicaments génériques neurologiques: 64,5 milliards de dollars
• Réduction moyenne des prix par les génériques: 80-85%

SCISPARC LTD. (SPRC) - Five Forces de Porter: Menace de nouveaux entrants

Barrières réglementaires élevées dans la recherche pharmaceutique et médicale sur le cannabis

Taux d'approbation de l'application de nouveau médicament FDA: 12% en 2022, avec un coût moyen de 161 millions de dollars par application réussie.

Exigences de capital importantes pour la recherche et le développement

Investissement moyen de R&D pour la thérapeutique cannabinoïde: 25 à 50 millions de dollars par an.

• Financement initial de phase de recherche: 5 à 10 millions de dollars
• Études précliniques: 3 à 7 millions de dollars
• Essais cliniques de phase I: 4 à 10 millions de dollars

Paysage de propriété intellectuelle complexe dans les thérapies cannabinoïdes

Expertise scientifique avancée nécessaire pour l'entrée du marché

Exigences minimales de l'équipe de recherche: 5-7 chercheurs au niveau du doctorat ayant une expertise spécialisée sur les cannabinoïdes.

Procédés d'essais cliniques substantiels et d'approbation réglementaire

Taux de réussite des essais cliniques pour les traitements neurologiques: 8,4% en 2022.

• Taux de réussite des essais de phase I: 13,1%
• Taux de réussite des essais de phase II: 11,6%
• Taux de réussite des essais de phase III: 7,2%

SciSparc Ltd. (SPRC) - Porter's Five Forces: Competitive rivalry

You're looking at the CNS disorder and pain management space, and honestly, the competitive rivalry SciSparc Ltd. faces is intense, dominated by large-cap pharmaceutical giants. These established players, like Johnson & Johnson, Eli Lilly, and Biogen, command massive research and development budgets and established distribution channels in areas where SciSparc Ltd. is trying to carve out a niche with its cannabinoid therapies. For instance, in the broader CNS Treatment and Therapy Market, which is projected to reach $136.3 billion in 2025, companies like Sanofi and Bristol-Myers Squibb are actively expanding pipelines in neurodegeneration and mental health care.

The financial reality for SciSparc Ltd. clearly reflects this competitive pressure. The company's interim financial statements for H1 2025, released on November 18, 2025, show that its sales for that period were only $0.461 million. That number confirms its minimal market share position when stacked against the multi-billion dollar revenues of its rivals. Also, the small market capitalization, hovering between approximately $3.89M and $4.82 million as of late November 2025, firmly establishes SciSparc Ltd. as a nano-cap industry player.

The competitive dynamic shifts when you look at the GERD device market, where SciSparc Ltd. is entering with the MUSE™ system following its intellectual property acquisition. Here, the rivalry is against established medical device behemoths. To give you a sense of the scale, Medtronic Plc holds a 20% share in the GERD device market, which is projected to grow from $1.3 billion in 2025 to approximately $1.9 billion by 2035. SciSparc Ltd. is aiming to replicate a licensing model that previously generated a $3 million upfront payment for Xylo in Greater China.

Here's a quick comparison mapping SciSparc Ltd.'s new GERD focus against a market leader:

The threat of new competition in this device segment is real, even as SciSparc Ltd. enters it. You have to consider the established players who already have deep regulatory experience and global reach. The anti-reflux device market historically featured dominant competitors like Johnson & Johnson, which offers the LINX® reflux management system. This means SciSparc Ltd. needs its differentiation to stick.

Consider the competitive factors SciSparc Ltd. must navigate in the GERD device space:

• Established players like Johnson & Johnson and Restech hold significant historical presence.
• Device development costs can range from $2.5 to $8.0 million.
• FDA approval processes add 18 to 24 months to development cycles.
• Implementation costs can extend by 30-40% due to training curves.
• The overall market CAGR is projected at 3.6% between 2025 and 2035.

SciSparc Ltd. (SPRC) - Porter's Five Forces: Threat of substitutes

You're looking at the competitive landscape for SciSparc Ltd. (SPRC), and the threat of substitutes is definitely a major headwind, especially given the company's dual focus on clinical-stage pharma and online sales. Honestly, for a company with a market cap hovering around $3.96M as of late 2025, the sheer scale of the substitute markets is what you need to focus on.

High Threat from Existing, Approved, and Often Generic Drugs

For SCI-110, targeting Tourette Syndrome (TS) and Alzheimer's disease and agitation, the existing standard of care presents a formidable barrier. For Alzheimer's, the global drugs market is estimated to be valued at USD 5.64 Bn in 2025. Within that, established, often generic, drug classes already command significant share. For instance, Cholinesterase Inhibitors are projected to account for 40.5% of the Alzheimer's drugs market share in 2025. These existing treatments are accessible and have proven clinical benefit for symptom management, which is what most patients rely on today. On the generic side generally, the year-over-year (YoY) oral solid price change as of January 2025 was 19%, indicating a mature, cost-competitive segment that SciSparc Ltd. must overcome with superior efficacy data from its Phase 2b TS trial and ongoing Alzheimer's work.

Very High Threat for the Online Sales Segment

SciSparc Ltd.'s Online Sales segment, which moves hemp-based products, faces an ocean of competition. The global nutraceuticals market was already valued at USD 500.62 billion in 2025, and the US market alone was anticipated to produce revenue of US$ 161.8 billion in 2024. This massive market is flooded with countless competing wellness products. To be fair, the online distribution channel within the US nutraceuticals market is expected to grow at a notable CAGR of 10.7%, but that growth benefits everyone, meaning SciSparc Ltd.'s hemp-based offerings are fighting for a tiny slice of a gigantic, rapidly expanding pie.

Here's a quick look at the scale of the substitute market for the Online Sales segment:

Non-Pharmacological Treatments are Viable Substitutes

For CNS disorders like TS, non-drug interventions are established alternatives. Deep Brain Stimulation (DBS) is a prime example, which is even being investigated for TS itself. The Deep Brain Stimulator market was projected to be USD 1.4 billion in 2025. You see, this isn't just theoretical; it's a multi-billion dollar industry with established procedures. For instance, approximately 12,000 DBS procedures occur in the United States annually. If SCI-110 fails to show compelling superiority over existing therapies or behavioral interventions, these procedural substitutes remain highly viable options for patients.

The MUSETM GERD Device Faces Substitution

SciSparc Ltd. recently announced a binding term sheet to acquire patents for endoscopic systems, including the MUSE™ system, to enter the GERD device market. This market itself is subject to substitution pressure. While the global GERD device market is projected to reach $3.03 billion by 2030, the MUSE™ system competes against established, traditional surgical procedures and other existing endoscopic devices. The threat here is that established surgical centers may prefer existing, well-understood procedures or devices with long-term outcome data over a newly commercialized system, even if the new system is less invasive. The company's plan is to replicate a successful commercialization model in Greater China across North America, Europe, and Latin America, but the established competition in those regions is significant.

The substitutes are large, entrenched, and growing. Finance: review the projected cost of goods sold for the acquired GERD IP against the established market pricing for competing endoscopic procedures by Q1 2026.

SciSparc Ltd. (SPRC) - Porter's Five Forces: Threat of new entrants

You're assessing the competitive landscape for SciSparc Ltd. (SPRC), and the threat of new entrants paints a dual picture, sharply divided by the company's two main operational areas: clinical-stage pharmaceuticals and nutraceuticals.

In the core pharmaceutical segment, the threat of new entrants is decidedly low. Honestly, getting into this space requires deep pockets and a tolerance for extreme regulatory hurdles. New players face massive research and development (R&D) costs and the stringent, multi-phase approval process mandated by the U.S. Food and Drug Administration (FDA). The capital intensity is clear; for the half year ended June 30, 2025, SciSparc Ltd. reported a net loss of $9.33 million, which starkly illustrates the cash burn required to advance drug candidates like SCI-110. This financial reality acts as a significant deterrent for most potential competitors.

The high capital requirement, evidenced by SciSparc Ltd.'s H1 2025 net loss of $9.33 million against sales of only $0.461 million for the same period, deters most new entrants who cannot sustain such early-stage development losses. It's a classic barrier to entry in biotech.

Conversely, the nutraceutical and hemp-based product market presents a high threat. This segment, where SciSparc Ltd. has a subsidiary focused on hemp seed oil-based products, has significantly lower entry barriers. As you know, the nutraceutical industry is generally not regulated as heavily as pharmaceuticals, meaning new entrants do not face the same pre-market approval or extensive clinical trial requirements for supplements. This ease of access means competition can spring up quickly, often based on lower pricing, especially from established global manufacturers.

Patent protection on key drug candidates offers SciSparc Ltd. a temporary, but strong, barrier against direct competition for specific treatments. For instance, the company is developing SCI-110 for Tourette Syndrome and Alzheimer's disease agitation. Furthermore, a U.S. patent application covering a combination therapy involving MEAI and PEA for binge behavior disorders was published as recently as October 20, 2025, providing a layer of exclusivity for that specific innovation.

Here's a quick look at the forces shaping the pharmaceutical entry barrier:

The contrast in entry barriers across SciSparc Ltd.'s business lines is stark:

• Pharmaceuticals: High capital, high regulation, patent defense.
• Nutraceuticals: Low capital, minimal regulation, high fragmentation.
• Hemp-based products: Exposure to low-cost competition from established players.
• Patent strength: Protects specific cannabinoid-based assets temporarily.

The existence of fringe players in the supplement space suggests that quality control can be poor, which is a risk for the entire sector, but it confirms that setting up a basic product line is relatively easy.

Finance: draft 13-week cash view by Friday.